Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015 (2015), Article ID 951532, 14 pages
http://dx.doi.org/10.1155/2015/951532
Research Article

Procalcitonin, MR-Proadrenomedullin, and Cytokines Measurement in Sepsis Diagnosis: Advantages from Test Combination

1Clinical Pathology and Microbiology Laboratory, University Hospital Campus Bio-Medico of Rome, 00128 Rome, Italy
2Department of Infectious, Parasitic, and Immune-Mediated Diseases, Epidemiology Unit, Reference Centre on Phylogeny, Molecular Epidemiology, and Microbial Evolution (FEMEM), National Institute of Health, 00161 Rome, Italy

Received 10 April 2015; Accepted 13 October 2015

Academic Editor: Dinesh Kumbhare

Copyright © 2015 Silvia Angeletti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H.-C. Kung, D. L. Hoyert, J. Xu, and S. L. Murphy, “Deaths: final data for 2005,” National Vital Statistics Reports, vol. 56, no. 10, pp. 1–120, 2008. View at Google Scholar · View at Scopus
  2. A. Melamed and F. J. Sorvillo, “The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data,” Critical Care, vol. 13, no. 1, article R28, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Kumar, N. Kumar, A. Taneja et al., “Nationwide trends of severe sepsis in the 21st century (2000–2007),” Chest, vol. 140, no. 5, pp. 1223–1231, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. G. S. Martin, D. M. Mannino, S. Eaton, and M. Moss, “The epidemiology of sepsis in the United States from 1979 through 2000,” The New England Journal of Medicine, vol. 348, no. 16, pp. 1546–1554, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Russell, “Management of sepsis,” The New England Journal of Medicine, vol. 355, no. 16, pp. 1699–1713, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. D. C. Angus, W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky, “Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care,” Critical Care Medicine, vol. 29, no. 7, pp. 1303–1310, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. R. P. Dellinger, M. M. Levy, A. Rhodes et al., “Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012,” Intensive Care Medicine, vol. 39, no. 2, pp. 165–228, 2013. View at Publisher · View at Google Scholar
  8. A. Lever and I. Mackenzie, “Sepsis: definition, epidemiology, and diagnosis,” British Medical Journal, vol. 335, no. 7625, pp. 879–883, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. R. S. Hotchkiss and I. E. Karl, “The pathophysiology and treatment of sepsis,” The New England Journal of Medicine, vol. 348, no. 2, pp. 138–150, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. N. C. Riedemann and P. A. Ward, “Anti-inflammatory strategies for the treatment of sepsis,” Expert Opinion on Biological Therapy, vol. 3, no. 2, pp. 339–350, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Matsuda, A. Jacob, R. Wu et al., “Novel therapeutic targets for sepsis: regulation of exaggerated inflammatory responses,” Journal of Nippon Medical School, vol. 79, no. 1, pp. 4–18, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. V. Lvovschi, L. Arnaud, C. Parizot et al., “Cytokine profiles in sepsis have limited relevance for stratifying patients in the emergency department: a prospective observational study,” PLoS ONE, vol. 6, no. 12, Article ID e28870, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Mera, D. Tatulescu, C. Cismaru et al., “Multiplex cytokine profiling in patients with sepsis,” Acta Pathologica, Microbiologica, et Immunologica Scandinavica, vol. 119, no. 2, pp. 155–163, 2011. View at Publisher · View at Google Scholar
  14. X.-J. Xu, Y.-M. Tang, H. Song et al., “A multiplex cytokine score for the prediction of disease severity in pediatric hematology/oncology patients with septic shock,” Cytokine, vol. 64, no. 2, pp. 590–596, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Gouel-Chéron, B. Allaouchiche, C. Guignant, F. Davin, B. Floccard, and G. Monneret, “Early interleukin-6 and slope of monocyte human leukocyte antigen-DR: a powerful association to predict the development of sepsis after major trauma,” PLoS ONE, vol. 7, no. 3, Article ID e33095, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Vänskä, I. Koivula, E. Jantunen et al., “IL-10 combined with procalcitonin improves early prediction of complications of febrile neutropenia in hematological patients,” Cytokine, vol. 60, no. 3, pp. 787–792, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Assicot, D. Gendrel, H. Carsin, J. Raymond, J. Guilbaud, and C. Bohuon, “High serum procalcitonin concentrations in patients with sepsis and infection,” The Lancet, vol. 341, no. 8844, pp. 515–518, 1993. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Angeletti, S. Spoto, M. Fogolari et al., “Diagnostic and prognostic role of procalcitonin (PCT) and MR-pro-Adrenomedullin (MR-proADM) in bacterial infections,” APMIS, vol. 123, no. 9, pp. 740–748, 2015. View at Publisher · View at Google Scholar
  19. D. Kojic, B. H. Siegler, F. Uhle et al., “Are there new approaches for diagnosis, therapy guidance and outcome prediction of sepsis?” World Journal of Experimental Medicine, vol. 5, no. 2, pp. 50–63, 2015. View at Google Scholar
  20. Y. Hirata, C. Mitaka, K. Sato et al., “Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 4, pp. 1449–1453, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Kitamura, K. Kangawa, M. Kawamoto et al., “Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma,” Biochemical and Biophysical Research Communications, vol. 425, no. 3, pp. 548–555, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Zhou, Z. F. Ba, I. H. Chaudry, and P. Wang, “Adrenomedullin binding protein-1 modulates vascular responsiveness to adrenomedullin in late sepsis,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 283, no. 3, pp. R553–R560, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Angeletti, F. Battistoni, M. Fioravanti, S. Bernardini, and G. Dicuonzo, “Procalcitonin and mid-regional pro-adrenomedullin test combination in sepsis diagnosis,” Clinical Chemistry and Laboratory Medicine, vol. 51, no. 5, pp. 1059–1067, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Suberviola, A. Castellanos-Ortega, A. R. Ruiz, M. Lopez-Hoyos, and M. Santibañez, “Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission,” Intensive Care Medicine, vol. 39, no. 11, pp. 1945–1952, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. W. A. Knaus, E. A. Draper, D. P. Wagner, and J. E. Zimmerman, “APACHE II: a severity of disease classification system,” Critical Care Medicine, vol. 13, no. 10, pp. 818–829, 1985. View at Publisher · View at Google Scholar · View at Scopus
  26. J.-L. Vincent, A. de Mendonça, F. Cantraine et al., “Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on ‘sepsis-related problems’ of the European Society of Intensive Care Medicine,” Critical Care Medicine, vol. 26, no. 11, pp. 1793–1800, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. A. C. Kajdacsy-Balla Amaral, F. M. Andrade, R. Moreno, A. Artigas, F. Cantraine, and J.-L. Vincent, “Use of the sequential organ failure assessment score as a severity score,” Intensive Care Medicine, vol. 31, no. 2, pp. 243–249, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Angeletti, G. Dicuonzo, A. D'Agostino et al., “Turnaround time of positive blood cultures after the introduction of matrix-assisted laser desorption-ionization time-of-flight mass spectrometry,” New Microbiologica, vol. 38, no. 3, pp. 379–386, 2015. View at Google Scholar
  29. P. Caruhel, C. Mazier, J. Kunde, N. G. Morgenthaler, and B. Darbouret, “Homogeneous time-resolved fluoroimmunoassay for the measurement of midregional proadrenomedullin in plasma on the fully automated system B.R.A.H.M.S KRYPTOR,” Clinical Biochemistry, vol. 42, no. 7-8, pp. 725–728, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Berrahmoune, J. V. Lamont, B. Herbeth, P. S. FitzGerald, and S. Visvikis-Siest, “Biological determinants of and reference values for plasma interleukin-8, monocyte chemoattractant protein-1, epidermal growth factor, and vascular endothelial growth factor: results from the STANISLAS cohort,” Clinical Chemistry, vol. 52, no. 3, pp. 504–510, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. C. M. Florkowski, “Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests,” The Clinical Biochemist Reviews, vol. 29, supplement 1, pp. S83–S87, 2008. View at Google Scholar
  32. A. Albert, “On the use and computation of likelihood ratios in clinical chemistry,” Clinical Chemistry, vol. 28, no. 5, pp. 1113–1119, 1982. View at Google Scholar · View at Scopus
  33. M. T. Lotze, L. W. Frana, S. O. Sharrow, R. J. Robb, and S. A. Rosenberg, “In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2,” Journal of Immunology, vol. 134, no. 1, pp. 157–166, 1985. View at Google Scholar · View at Scopus
  34. P. J. Conlon, S. Tyler, K. H. Grabstein, and P. Morrissey, “Interleukin-4 (B-cell stimulatory factor-1) augments the in vivo generation of cytotoxic cells in immunosuppressed animals,” Biotechnology Therapeutics, vol. 1, no. 1, pp. 31–41, 1989. View at Google Scholar · View at Scopus
  35. F. Travaglino, B. De Berardinis, L. Magrini et al., “Utility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score,” BMC Infectious Diseases, vol. 12, no. 8, article 184, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. M. C. Morris, E. A. Gilliam, and L. Li, “Innate immune programing by endotoxin and its pathological consequences,” Frontiers in Immunology, vol. 5, article 680, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Rizzetto, C. De Filippo, D. Rivero, S. Riccadonna, L. Beltrame, and D. Cavalieri, “Systems biology of host–mycobiota interactions: dissecting dectin-1 and dectin-2 signalling in immune cells with DC-ATLAS,” Immunobiology, vol. 218, no. 11, pp. 1428–1437, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Debiane, R. Y. Hachem, I. Al Wohoush et al., “The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer,” Critical Care Medicine, vol. 42, no. 12, pp. 2500–2507, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Surbatovic, N. Popovic, D. Vojvodic et al., “Cytokine profile in severe gram-positive and gram-negative abdominal sepsis,” Scientific Reports, vol. 5, article 11355, 2015. View at Publisher · View at Google Scholar